Rigel Pharmaceuticals (NASDAQ: RIGL) open the trading on Wednesday, with great promise as it jumped 4.42% to $27.88, before settling in for the price of $26.70 at the close. Taking a more long-term approach, RIGL posted a 52-week range of $7.48-$29.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 26.32%. Meanwhile, its Annual Earning per share during the time was 19.96%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 120.53%. This publicly-traded company’s shares outstanding now amounts to $17.48 million, simultaneously with a float of $17.27 million. The organization now has a market capitalization sitting at $491.11 million. At the time of writing, stock’s 50-day Moving Average stood at $17.98, while the 200-day Moving Average is $13.12.
Rigel Pharmaceuticals (RIGL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Rigel Pharmaceuticals’s current insider ownership accounts for 1.98%, in contrast to 67.79% institutional ownership. According to the most recent insider trade that took place on Feb 05 ’24, this organization’s EVP, Chief Commercial Officer sold 8,918 shares at the rate of 1.14, making the entire transaction reach 10,167 in total value, affecting insider ownership by 349,093. Preceding that transaction, on Feb 02 ’24, Company’s EVP, Chief Commercial Officer sold 5,601 for 1.13, making the whole transaction’s value amount to 6,329. This particular insider is now the holder of 358,011 in total.
Rigel Pharmaceuticals (RIGL) Earnings and Revenue Records
Rigel Pharmaceuticals’s EPS increase for this current 12-month fiscal period is 120.53% and is forecasted to reach 0.98 in the upcoming year.
Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators
Let’s observe the current performance indicators for Rigel Pharmaceuticals (RIGL). It’s Quick Ratio in the last reported quarter now stands at 1.81. The Stock has managed to achieve an average true range (ATR) of 1.72. Alongside those numbers, its PE Ratio stands at $128.72, and its Beta score is 1.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.12. Similarly, its price to free cash flow for trailing twelve months is now 45.81.
In the same vein, RIGL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.22, a figure that is expected to reach 0.30 in the next quarter, and analysts are predicting that it will be 0.98 at the market close of one year from today.
Technical Analysis of Rigel Pharmaceuticals (RIGL)
[Rigel Pharmaceuticals, RIGL] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 72.03% While, its Average True Range was 1.86.
Raw Stochastic average of Rigel Pharmaceuticals (RIGL) in the period of the previous 100 days is set at 91.07%, which indicates a major rise in contrast to 85.76% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 163.99% that was higher than 90.85% volatility it exhibited in the past 100-days period.
